Polydatin protects against gouty nephropathy by inhibiting renal tubular cell pyroptosis

Xingliang Shi1,2, Lili Zhuang1,2, Zeqing Zhai1,2

  • 1Department of Rheumatology and Immunology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.

Abstract

Insights

Polydatin (PD) protects against gouty nephropathy (GN) in mice by inhibiting pyroptosis. This involves downregulating NLRP3, caspase-1, and gasdermin D (GSDMD) proteins, offering a potential therapeutic strategy for GN.

Area of Science:

  • Nephrology
  • Pharmacology
  • Cell Biology

Background:

  • Gouty nephropathy (GN) is a serious complication of gout, characterized by kidney damage.
  • Pyroptosis, a pro-inflammatory form of programmed cell death, plays a significant role in the pathogenesis of GN.
  • Identifying therapeutic agents that can mitigate GN progression by targeting pyroptosis is crucial.

Purpose of the Study:

  • To investigate the protective effects of polydatin (PD) against gouty nephropathy (GN) in a mouse model.
  • To elucidate the underlying mechanism of PD's action, focusing on its impact on pyroptosis and related proteins.

Main Methods:

  • A mouse model of GN was established using hypoxanthine and potassium oxonate.
  • Mice were treated with polydatin (PD) and compared to control and GN-only groups.
  • Kidney histology, serum markers (uric acid, BUN, creatinine), and protein expression (NLRP3, caspase-1, GSDMD) were analyzed.

Main Results:

  • Polydatin (PD) treatment significantly ameliorated kidney tissue damage in GN mice.
  • PD reversed abnormal levels of serum uric acid and blood urea nitrogen.
  • PD inhibited the expression of NLRP3, caspase-1, and GSDMD, thereby reducing renal tubular epithelial cell pyroptosis.

Conclusions:

  • Polydatin (PD) demonstrates a significant protective effect against gouty nephropathy (GN) in mice.
  • The protective mechanism involves the downregulation of NLRP3, caspase-1, and GSDMD proteins.
  • PD's inhibition of pyroptosis suggests its potential as a therapeutic agent for GN.

Related Concept Videos

Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
259
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
841
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
53
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
233
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K